Colloidal silver nanoparticles

Phase 1Small molecule

WWashington University School of Medicine

Colloidal silver nanoparticles is one of 42 small molecule programs targeting Sinusitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SinusitisActive, not recruiting

SinusitisPhase 1

Active, not recruiting

Competition

Competitive Landscape

94 competitors in Sinusitis

#DrugCompanyPhaseTrials

Ketek

Sanofi

Approved

2 2

Asmanex Hfa

PPerrigo Company

Approved

1 3

Tylenol

KKenvue Brands

Approved

1 4

Tobrex

VViatris Specialty LLC

Normodyne

Sporanox

SSebela Pharmaceuticals Development LLC

Asmanex

3 8

Biaxin

AbbVie

Phase 3

1 9

Flovent

GSK

Phase 3

1 10

Avelox

Bayer

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sinusitis1 trial

Silver Nanoparticle Investigation for Treating Chronic Sinusitis

Withdrawn·WWashington University School of Medicine·Phase 1·NCT03243201

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Colloidal silver nanoparticles. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Colloidal silver nanoparticles compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Colloidal silver nanoparticles. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Washington University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: WWashington University School of Medicine

Colloidal silver nanoparticles

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Sinusitis1 trial

References

Drug Info

Quick Facts

Related News